SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product ...
SpringWorks Therapeutics Inc (SWTX) Q4 2024 Earnings Report Preview: What To Expect
SpringWorks Therapeutics Inc (NASDAQ:SWTX) is set to release its Q4 2024 earnings on February 20, 2025. The consensus estimate for Q4 2024 revenue is $59.12 million, and the earnings are expected to ...
SpringWorks Therapeutics reports FY24 EPS ($3.48), consensus ($3.16)
Reports FY24 revenue $191.5M, consensus $190.85M. “We are very pleased with the strong execution of OGSIVEO in 2024 and believe that we are ...
Analysts Are Bullish on These Healthcare Stocks: Aura Biosciences Inc (AURA), Springworks Therapeutics (SWTX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aura Biosciences Inc (AURA – Research Report) ...
SpringWorks Therapeutics jumps after results, conference call cancellation
SpringWorks Therapeutics (NASDAQ:SWTX) jumped 10% in premarket trading after the firm reported its Q4 results and canceled ...
Hosted on MSN14h
SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect
SpringWorks Therapeutics Inc. (SWTX) shares surged more than 10% in Wednesday’s after-hours, signaling strong investor ...
STAT6h
Risky weight loss, grad school acceptance cuts, and more major biotech news of the day
Experts noted that rapid and extreme weight loss can introduce unique risks, such as a weakened immune system and malnourishment, as well as potentially too much muscle loss. They’re also concerned ...